keyword
MENU ▼
Read by QxMD icon Read
search

Dementia biomarker

keyword
https://www.readbyqxmd.com/read/28936940/-doctor-is-my-mother-suffering-from-dementia
#1
P Scheltens, F Gillissen, F H Bouwman, W M van der Flier
- The Netherlands health service features a stepwise diagnostic course in primary, secondary and tertiary care. In the diagnostic process for dementia the patient can go to the general practitioner, then to one of the 100 memory clinics and finally to one of the 4 academic Alzheimer centres.- The diagnostic process for dementia is described in the care practice guideline 'Dementia', the NHG (Dutch College of General Practitioners) practice guideline 'Dementia' and the multidisciplinary guideline 'Dementia diagnostics'...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/28936173/combining-spect-and-quantitative-eeg-analysis-for-the-automated-differential-diagnosis-of-disorders-with-amnestic-symptoms
#2
Yvonne Höller, Arne C Bathke, Andreas Uhl, Nicolas Strobl, Adelheid Lang, Jürgen Bergmann, Raffaele Nardone, Fabio Rossini, Harald Zauner, Margarita Kirschner, Amirhossein Jahanbekam, Eugen Trinka, Wolfgang Staffen
Single photon emission computed tomography (SPECT) and Electroencephalography (EEG) have become established tools in routine diagnostics of dementia. We aimed to increase the diagnostic power by combining quantitative markers from SPECT and EEG for differential diagnosis of disorders with amnestic symptoms. We hypothesize that the combination of SPECT with measures of interaction (connectivity) in the EEG yields higher diagnostic accuracy than the single modalities. We examined 39 patients with Alzheimer's dementia (AD), 69 patients with depressive cognitive impairment (DCI), 71 patients with amnestic mild cognitive impairment (aMCI), and 41 patients with amnestic subjective cognitive complaints (aSCC)...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28934192/metabolomics-and-cognition-in-african-american-adults-in-midlife-the-atherosclerosis-risk-in-communities-study
#3
J Bressler, B Yu, T H Mosley, D S Knopman, R F Gottesman, A Alonso, A R Sharrett, L M Wruck, E Boerwinkle
Clinical studies have shown alterations in metabolic profiles when patients with mild cognitive impairment and Alzheimer's disease dementia were compared to cognitively normal subjects. Associations between 204 serum metabolites measured at baseline (1987-1989) and cognitive change were investigated in 1035 middle-aged community-dwelling African American participants in the biracial Atherosclerosis Risk in Communities (ARIC) Study. Cognition was evaluated using the Delayed Word Recall Test (DWRT; verbal memory), the Digit Symbol Substitution Test (DSST; processing speed) and the Word Fluency Test (WFT; verbal fluency) at visits 2 (1990-1992) and 4 (1996-1998)...
July 18, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28931301/oxidative-stress-assessment-in-alzheimer-s-disease-a-clinic-setting-study
#4
Andrea Vergallo, Linda Giampietri, Filippo Baldacci, Leda Volpi, Lucia Chico, Cristina Pagni, Filippo Sean Giorgi, Roberto Ceravolo, Gloria Tognoni, Gabriele Siciliano, Ubaldo Bonuccelli
BACKGROUND: Oxidative stress (OS) is a physiological age-related brain process, dramatically overexpressed in neurodegenerative disorders like Alzheimer's disease (AD). Nevertheless, the pathophysiological role of OS in AD pathology has not been clarified yet. OS as a biomarker for AD is a controversial issue. A comparison of previous data is difficult due to a remarkable methodological variability. Most of the previous studies have shown higher levels of OS markers and lower antioxidant power in patients with dementia when compared to mild cognitive impairment (MCI) and healthy controls...
January 1, 2017: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/28930599/dissection-of-prodromal-alzheimer-s-disease
#5
Can Sheng, Yue Huang, Ying Han
Pathophysiological changes of Alzheimer's Disease (AD) begin decades before clinical symptoms become apparent, providing an important window for early diagnosis and intervention. Prodromal stage of AD, a great opportunity for effective treatment and postponing the disease onset, has drawn extensive attention. The application of different biomarkers including neuroimaging, biochemical substances and genes makes AD-related pathology detectable in vivo and exploring novel biomarkers with relatively non-invasive and low cost has intrigued a wide range of interests...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28930593/precision-medicine-of-frontotemporal-dementia-from-genotype-to-phenotype
#6
Xiang-Qian Che, Ning Song, Ying Gao, Ru-Jing Ren, Gang Wang
Frontotemporal dementia (FTD) is the second most common neurodegenerative  cause of early-onset dementia. FTD has an important genetic component contributing to its pathogenic mechanisms. Currently, extensive research on neuroimaging biomarkers and neurochemical biomarkers in FTD is being conducted to address the clinical need for a sensitive and specific diagnostic marker. Here, we review the advances in genetics, biomarkers and treatment of FTD and how this may represent a shift towards precision medicine...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28930543/eeg-and-erp-biomarkers-of-alzheimer-s-disease-a-critical-review
#7
Andras Horvath, Anna Szucs, Gabor Csukly, Anna Sakovics, Gabor Stefanics, Anita Kamondi
Here we critically review studies that used electroencephalography (EEG) or event-related potential (ERP) indices as a biomarker of Alzheimer's disease. In the first part we overview studies that relied on visual inspection of EEG traces and spectral characteristics of EEG. Second, we survey analysis methods motivated by dynamical systems theory (DST) as well as more recent network connectivity approaches. In the third part we review studies of sleep.  Next, we compare the utility of early and late ERP components in dementia research...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28929132/interplay-between-protein-glycosylation-pathways-in-alzheimer-s-disease
#8
Moran Frenkel-Pinter, Merav Daniel Shmueli, Chen Raz, Michaela Yanku, Shai Zilberzwige, Ehud Gazit, Daniel Segal
Deviations from the normal nucleoplasmic protein O-GlcNAcylation, as well as from normal protein sialylation and N-glycosylation in the secretory pathway, have been reported in Alzheimer's disease (AD). However, the interplay between the cytoplasmic protein O-GlcNAcylation and the secretory N-/O-glycosylation in AD has not been described. We present a comprehensive analysis of the N-, O-, and O-GlcNAc-glycomes in AD-affected brain regions as well as in AD patient serum. We detected marked differences in levels of glycan involved in both protein O-GlcNAcylation and N-/O-glycosylation between patients and healthy individuals and revealed brain region-specific glycosylation-related pathology in patients...
September 2017: Science Advances
https://www.readbyqxmd.com/read/28924872/-alzheimer-s-disease-from-auguste-deter-to-the-present-progress-disappointments-and-open-questions
#9
REVIEW
Johannes Pantel
AIM: The present article aims to provide a short overview of the discovery history, conceptual development, as well as on current neurobiological and pharmacological research questions in the field of Alzheimer's disease (AD). In view of the long hoped for but so far unachieved therapeutic breakthrough, this also includes a critical reflection of current research paradigms. MATERIAL AND METHODS: Starting from the first case report described by Alois Alzheimer in 1906, the historical impact of his seminal discovery is reconstructed...
September 18, 2017: Zeitschrift Für Gerontologie und Geriatrie
https://www.readbyqxmd.com/read/28923099/whole-blood-gene-expression-and-white-matter-hyperintensities
#10
Honghuang Lin, Claudia Satizabal, Zhijun Xie, Qiong Yang, Tianxiao Huan, Roby Joehanes, Chengping Wen, Peter J Munson, Alexa Beiser, Daniel Levy, Sudha Seshadri
BACKGROUND: White matter hyperintensities (WMH) are an important biomarker of cumulative vascular brain injury and have been associated with cognitive decline and an increased risk of dementia, stroke, depression, and gait impairments. The pathogenesis of white matter lesions however, remains uncertain. The characterization of gene expression profiles associated with WMH might help uncover molecular mechanisms underlying WMH. METHODS: We performed a transcriptome-wide association study of gene expression profiles with WMH in 3248 participants from the Framingham Heart Study using the Affymetrix Human Exon 1...
September 18, 2017: Molecular Neurodegeneration
https://www.readbyqxmd.com/read/28921611/dendritic-spines-provide-cognitive-resilience-against-alzheimer-s-disease
#11
Benjamin D Boros, Kelsey M Greathouse, Erik G Gentry, Kendall A Curtis, Elizabeth L Birchall, Marla Gearing, Jeremy H Herskowitz
OBJECTIVE: Neuroimaging and other biomarker assays suggest that the pathological processes of Alzheimer's disease (AD) initiate years prior to clinical dementia onset. However some 30%-50% of older individuals that harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia. We hypothesized that in cases with AD pathology structural changes in dendritic spines would distinguish individuals that had or did not have clinical dementia...
September 16, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28918757/relationship-between-cognitive-performance-and-measures-of-neurodegeneration-among-hispanic-and-white-non-hispanic-individuals-with-normal-cognition-mild-cognitive-impairment-and-dementia
#12
Shanna L Burke, Miriam J Rodriguez, Warren Barker, Maria T Greig-Custo, Monica Rosselli, David A Loewenstein, Ranjan Duara
OBJECTIVES: The aim of this study was to determine the presence and severity of potential cultural and language bias in widely used cognitive and other assessment instruments, using structural MRI measures of neurodegeneration as biomarkers of disease stage and severity. METHODS: Hispanic (n=75) and White non-Hispanic (WNH) (n=90) subjects were classified as cognitively normal (CN), amnestic mild cognitive impairment (aMCI) and mild dementia. Performance on the culture-fair and educationally fair Fuld Object Memory Evaluation (FOME) and Clinical Dementia Rating Scale (CDR) between Hispanics and WNHs was equivalent, in each diagnostic group...
September 18, 2017: Journal of the International Neuropsychological Society: JINS
https://www.readbyqxmd.com/read/28918286/identifying-combinatorial-biomarkers-by-association-rule-mining-in-the-camd-alzheimer-s-database
#13
Balázs Szalkai, Vince K Grolmusz, Vince I Grolmusz
The concept of combinatorial biomarkers was conceived when it was noticed that simple biomarkers are often inadequate for recognizing and characterizing complex diseases. Here we present an algorithmic search method for complex biomarkers which may predict or indicate Alzheimer's disease (AD) and other kinds of dementia. We show that our method is universal since it can describe any Boolean function for biomarker discovery. We applied data mining techniques that are capable to uncover implication-like logical schemes with detailed quality scoring...
August 17, 2017: Archives of Gerontology and Geriatrics
https://www.readbyqxmd.com/read/28912709/extending-xnat-platform-with-an-incremental-semantic-framework
#14
Santiago Timón, Mariano Rincón, Rafael Martínez-Tomás
Informatics increases the yield from neuroscience due to improved data. Data sharing and accessibility enable joint efforts between different research groups, as well as replication studies, pivotal for progress in the field. Research data archiving solutions are evolving rapidly to address these necessities, however, distributed data integration is still difficult because of the need of explicit agreements for disparate data models. To address these problems, ontologies are widely used in biomedical research to obtain common vocabularies and logical descriptions, but its application may suffer from scalability issues, domain bias, and loss of low-level data access...
2017: Frontiers in Neuroinformatics
https://www.readbyqxmd.com/read/28912672/maximizing-the-potential-of-longitudinal-cohorts-for-research-in-neurodegenerative-diseases-a-community-perspective
#15
Catherine J Moody, Derick Mitchell, Grace Kiser, Dag Aarsland, Daniela Berg, Carol Brayne, Alberto Costa, Mohammad A Ikram, Gail Mountain, Jonathan D Rohrer, Charlotte E Teunissen, Leonard H van den Berg, Joanna M Wardlaw
Despite a wealth of activity across the globe in the area of longitudinal population cohorts, surprisingly little information is available on the natural biomedical history of a number of age-related neurodegenerative diseases (ND), and the scope for intervention studies based on these cohorts is only just beginning to be explored. The Joint Programming Initiative on Neurodegenerative Disease Research (JPND) recently developed a novel funding mechanism to rapidly mobilize scientists to address these issues from a broad, international community perspective...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28906268/new-pet-markers-for-the-diagnosis-of-dementia
#16
Pierre Payoux, Anne Sophie Salabert
PURPOSE OF REVIEW: To present the new PET markers that could become in the coming years, relevant to advanced clinical approaches to dementia diagnosis, drug trials, and treatment strategies and discuss their advantages and limitations. RECENT FINDINGS: The most advanced new PET tracers are the markers of the amyloid plaques, the τ compounds and the tracers of the translocator protein as markers of neuroinflammation. The main advantages but also the weaknesses of each of these markers are discussed...
September 12, 2017: Current Opinion in Neurology
https://www.readbyqxmd.com/read/28902409/binswanger-s-disease-biomarkers-in-the-inflammatory-form-of-vascular-cognitive-impairment-and-dementia
#17
REVIEW
Gary A Rosenberg
Vascular cognitive impairment and dementia (VCID) is a major public health concern because of the increased incidence of vascular disease in the aging population and the impact of vascular disease on Alzheimer's disease. VCID is a heterogeneous group of diseases for which there are no proven treatments. Biomarkers can be used to select more homogeneous populations. Small vessel disease is the most prevalent form of VCID and is the optimal form for treatment trials because there is a progressive course with characteristic pathological changes...
September 13, 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/28899429/amyloid-independent-atrophy-patterns-predict-time-to-progression-to-dementia-in-mild-cognitive-impairment
#18
Mara Ten Kate, Frederik Barkhof, Pieter Jelle Visser, Charlotte E Teunissen, Philip Scheltens, Wiesje M van der Flier, Betty M Tijms
BACKGROUND: Amyloid pathology in subjects with mild cognitive impairment (MCI) is an important risk factor for progression to dementia due to Alzheimer's disease. Predicting the onset of dementia is challenging even in the presence of amyloid, as time to progression varies considerably among patients and depends on the onset of neurodegeneration. Survival analysis can account for variability in time to event, but has not often been applied to MRI measurements beyond singular predefined brain regions such as the hippocampus...
September 12, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28893185/factors-that-influence-the-levels-of-cerebrospinal-fluid-biomarkers-in-memory-clinic-patients
#19
Anne-Brita Knapskog, Rannveig Sakshaug Eldholm, Anne Braekhus, Knut Engedal, Ingvild Saltvedt
BACKGROUND: The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ), phospho tau (P-tau) and total tau (T-tau) are used increasingly to support a clinical diagnosis of Alzheimer's disease. The diagnostic power of these biomarkers has been reported to vary among different studies' results. The results are poorer when heterogeneous groups of patients have been included compared to studies where patients with Alzheimer's dementia (AD) and healthy controls have been studied. The aim of this study was to examine if age, APOE genotype and sex were associated with the levels of CSF biomarkers among patients referred to a memory clinic...
September 11, 2017: BMC Geriatrics
https://www.readbyqxmd.com/read/28890893/proximate-mediators-of-microvascular-dysfunction-at-the-blood-brain-barrier-neuroinflammatory-pathways-to-neurodegeneration
#20
REVIEW
Barry W Festoff, Ravi K Sajja, Luca Cucullo
Current projections are that by 2050 the numbers of people aged 65 and older with Alzheimer's disease (AD) in the US may increase threefold while dementia is projected to double every 20 years reaching ~115 million by 2050. AD is clinically characterized by progressive dementia and neuropathologically by neuronal and synapse loss, accumulation of amyloid plaques, and neurofibrillary tangles (NFTs) in specific brain regions. The preclinical or presymptomatic stage of AD-related brain changes may begin over 20 years before symptoms occur, making development of noninvasive biomarkers essential...
2017: BioMed Research International
keyword
keyword
16715
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"